ClinicalTrials.gov Identifier: NCT02761499
United Orthopedic Corporation is sponsoring a post market study (PMS) to evaluate the clinical performance of the U-Motion II+ Acetabular System and the UTF Reduced Stem, associated surgical instruments, and surgical technique. The devices used in this PMS are cleared to market by the Food and Drug Administration (FDA) and will be used in accordance with the cleared labeling and indications for use.
Intended Use of the Study Device
The U-Motion II+ Acetabular System and the UTF Reduced Stem used in this study are cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.
The U-Motion II+ Acetabular System and UTF Reduced Stem are intended for use in subjects who require primary THA for reduction or relief of pain and/or improved hip function.
Duration of the Study
Clinical Trial Locations and Additional Sites
Currently, the study is ongoing at five (5) locations throughout the US. To learn more about qualifying as a patient for this study, please contact UOC USA, INC. or a study site located near you (study sites listed below).
We are also currently recruiting additional clinical sites. If you are interested in participating as an investigator surgeon please contact:
The following locations are the current active clinical study sites for this study:
Hospital for Special Surgery
New York, NY